Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
88.70
+14.18 (19.03%)
Jul 22, 2026, 4:00 PM EDT - Market closed
Arrowhead Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Arrowhead Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $100.09. The average 1-year stock price forecast is 12.84% higher than the current stock price, while the lowest is $85 (-4.17%) and the highest is $120 (+35.29%).
Price Target: $100.09 (+12.84%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Arrowhead Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 8 |
| Buy | 2 | 2 | 3 | 4 | 4 | 4 |
| Hold | 3 | 3 | 2 | 2 | 2 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 13 | 13 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Buy Maintains $90 → $115 | Buy | Maintains | $90 → $115 | +29.65% | Jul 22, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $100 | Buy | Reiterates | $100 | +12.74% | Jul 22, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $95 | Buy | Maintains | $95 | +7.10% | Jul 22, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Initiates $98 | Buy | Initiates | $98 | +10.48% | Jul 14, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $110 | Buy | Reiterates | $110 | +24.01% | Jun 30, 2026 |
Financial Forecast
Revenue This Year
442.33M
from 829.45M
Decreased by -46.67%
Revenue Next Year
324.49M
from 442.33M
Decreased by -26.64%
EPS This Year
-3.08
from -0.01
EPS Next Year
-4.57
from -3.08
EPS and Forward PE are based on non-GAAP adjusted numbers.